Second skin: Microfluidic patch analyzes sweat during exercise

It turns out, sweat can tell you more than just when it's time to find a tall glass of lemonade. Researchers at Northwestern University in Evanston, Illinois, have developed a patch that measures the wearer’s perspiration to show how his or her body is responding to exercise.

Applied directly to the skin, the patch is roughly the size of a quarter and can monitor key biomarkers regarding hydration and glucose levels.

“The intimate skin interface created by this wearable, skin-like microfluidic system enables new measurement capabilities not possible with the kinds of absorbent pads and sponges currently used in sweat collection,” said John A. Rogers, who led the multi-institution research team.

Developers of the patch claim the sweat analysis device features a number of innovations, including:

  • The device can capture, store and analyze sweat in situ in real-time.
  • The device can quantitatively determine biomarker levels using colorimetric analysis.
  • A power source is not required to display the results; instead, a smartphone camera and app are used to read the biomarker change.

Check out the full story and accompanying video here:

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.